BioAmber Inc.
| Company Name | BioAmber Inc. |
| Stock Symbol | BIOA |
| Class Period | July 15, 2014 to March 31, 2017 |
| Lead Plaintiff Motion Deadline | May 17, 2017 |
The Firm is investigating potential claims on behalf of investors of BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) concerning the Company and its officers’ possible violations of federal securities laws.
On March 16, 2017, BioAmber disclosed its financial results for the 2016 fiscal year, revealing that the Company had failed to meet its predicted revenue forecast by $1.3 million. Among other things, the Company’s President Fabrice Orecchioni blamed the disappointing results on “pricing pressures” and “a disruption from a large customer.” Following this news, BioAmber stock declined, falling to just $2.16 per share as of April 3, 2017.
Then, on March 31, 2017, the Company announced that Mario Saucier would cease serving as the Company’s Chief Financial Officer. On this news, the Company’s share price fell approximately 6% during intraday trading on April 3, 2017, thereby injuring investors.
If you purchased BioAmber securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Submit Your Information
If you suffered a loss on your BioAmber Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.